Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Hai-Yan XuQuan ZhangLi LiangJunling LiZhefeng LiuWeihua LiLu YangGuangjian YangFei XuJianming YingShucai ZhangYan WangPublished in: Cancer medicine (2020)
First-line therapy with crizotinib is more beneficial than platinum-based chemotherapy in patients with advanced NSCLC with different ROS1 fusion variants. Patients harboring CD74 fusion variants appear to respond better to crizotinib.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- copy number
- end stage renal disease
- cell death
- dna damage
- chronic kidney disease
- ejection fraction
- reactive oxygen species
- newly diagnosed
- locally advanced
- peritoneal dialysis
- small cell lung cancer
- prognostic factors
- tyrosine kinase
- squamous cell carcinoma
- gene expression
- oxidative stress
- dna methylation
- chemotherapy induced
- brain metastases